Technical Analysis for BPMC - Blueprint Medicines Corporation

Grade Last Price % Change Price Change
grade A 100.24 0.72% 0.72
BPMC closed up 0.72 percent on Monday, March 19, 2018, on approximately normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Flat
See historical BPMC trend table...

Date Alert Name Type % Chg
Mar 19 Multiple of Ten Bullish Other 0.00%
Mar 19 Wide Bands Range Expansion 0.00%
Mar 16 Slingshot Bullish Bullish Swing Setup 0.72%
Mar 16 Multiple of Ten Bearish Other 0.72%
Mar 16 Wide Bands Range Expansion 0.72%
Mar 15 Shooting Star Candlestick Bearish -2.63%
Mar 15 New 52 Week Closing High Bullish -2.63%
Mar 15 Expansion Breakout Bullish Swing Setup -2.63%
Mar 15 New 52 Week High Strength -2.63%
Mar 15 Wide Bands Range Expansion -2.63%

Older signals for BPMC ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company's lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor, as well as targets the KIT D816V mutation; and BLU-554, an orally available, potent, selective, and irreversible inhibitor, which targets FGFR4. It is also developing a drug candidate to target RET, a receptor tyrosine kinase that can becomes abnormally activated when a portion of the gene that encodes RET is joined to part of another gene; and RET resistant mutants that would arise from treatment with first generation therapies, as well as a program that targets rare genetic diseases. The company has a research, development, and commercialization agreement with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is based in Cambridge, Massachusetts.
Is BPMC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 109.0
52 Week Low 34.38
Average Volume 340,186
200-Day Moving Average 65.9881
50-Day Moving Average 85.1902
20-Day Moving Average 94.541
10-Day Moving Average 99.983
Average True Range 4.9942
ADX 34.34
+DI 29.76
-DI 11.68
Chandelier Exit (Long, 3 ATRs ) 94.0174
Chandelier Exit (Short, 3 ATRs ) 95.0926
Upper Bollinger Band 106.9393
Lower Bollinger Band 82.1427
Percent B (%b) 0.73
BandWidth 26.228409
MACD Line 5.0512
MACD Signal Line 4.9262
MACD Histogram 0.1251
Fundamentals Value
Market Cap 3.92 Billion
Num Shares 39.1 Million
EPS -3.12
Price-to-Earnings (P/E) Ratio -32.13
Price-to-Sales 103.31
Price-to-Book 7.06
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 105.16
Resistance 3 (R3) 105.06 103.33 104.34
Resistance 2 (R2) 103.33 102.07 103.38 104.07
Resistance 1 (R1) 101.78 101.30 102.56 101.88 103.79
Pivot Point 100.05 100.05 100.43 100.10 100.05
Support 1 (S1) 98.50 98.79 99.28 98.60 96.69
Support 2 (S2) 96.77 98.02 96.82 96.41
Support 3 (S3) 95.22 96.77 96.14
Support 4 (S4) 95.32